Related Experiment Video
Updated: Jul 5, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
Antidiabetic potential of thiazolidinedione derivatives with efficient design, molecular docking, structural activity
Anchal Sharma1, Nitish Kumar2, Harmandeep Kaur Gulati2
1Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143005, India. anchalsharma4619@gmail.com.
Abstract:
Thiazolidinedione has been used successfully by medicinal chemists all over the world in the development of potent antidiabetic derivatives. The few compounds with excellent antidiabetic potency that we have identified in this review could be used as a lead for further research into additional antidiabetic mechanisms. The information provided in this review regarding the design, biological activity, structure-activity relationships, and docking studies may be useful for scientists who wish to further explore this scaffold in order to fully utilize its biological potential and develop antidiabetic agents that would overcome the limitations of currently available medications for the treatment of diabetes. This review outlines the antidiabetic potential of Thiazolidinedione-based derivatives that have been published in the year 2021- till date.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Oral Hypoglycemic Agents: Glinides
Antihypertensive Drugs: Thiazide-Class Diuretics
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas